- Ethical Holdings reported a net loss of L2.5 million ($4 million),or L0.17 per share, for the second quarter of 1997, an increase over the same period in 1996 in which the group posted a net loss of L1.3 million, or L0.09 per share. This is due, it says, to a 20% increase in R&D costs to L5.5 million, plus interest payable and higher-than-expected losses from associate companies. The operating loss was L2.7 million versus L3 million in same-period 1996. Revenues were up 29% to L6.3 million for the year to date.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze